IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Moderate Buy” by Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has earned a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $241.4118.

Several research analysts have recently weighed in on IQV shares. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. UBS Group boosted their price objective on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus upped their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup upped their price target on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Truist Financial reiterated a “buy” rating and issued a $265.00 price target (up previously from $235.00) on shares of IQVIA in a research note on Wednesday.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IQV. Artisan Partners Limited Partnership acquired a new position in IQVIA in the 2nd quarter valued at about $515,772,000. Norges Bank acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $270,160,000. AQR Capital Management LLC grew its position in shares of IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after purchasing an additional 854,732 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.0%

IQVIA stock opened at $216.43 on Tuesday. The firm has a market capitalization of $36.86 billion, a PE ratio of 29.69, a P/E/G ratio of 2.43 and a beta of 1.32. The company’s 50-day moving average is $197.12 and its 200-day moving average is $173.95. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $225.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.